Completed PHASE2 INTERVENTIONAL 1-arm NCT00404066

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

Phase II Neoadjuvant Chemotherapy Trial in Clinical Stage II/III Her2Neu Positive Breast Cancer With Sequential AC -> Docetaxel With Concurrent Dual EGFR Kinase Blockade by GW572016 (Lapatinib) Followed by 1 Year Adjuvant Trastuzumab

Sponsor: George Albert Fisher

Conditions Breast Cancer Metastatic Breast Cancer

Interventions Cyclophosphamide Dexamethasone Docetaxel Doxorubicin Filgrastim Lapatinib Pegfilgrastim Trastuzumab

Updated 7 times since 2017 Last updated: Nov 28, 2017 Started: Oct 31, 2006 Primary completion: Dec 31, 2010 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00404066, this PHASE2 trial focuses on Breast Cancer and Metastatic Breast Cancer and remains completed. Sponsored by George Albert Fisher, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2018 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jan 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

George Albert Fisher
GlaxoSmithKline
Sanofi

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Jose, United States
• Stanford, United States